Bank of America Corp DE Has $1.03 Million Stock Holdings in Protara Therapeutics, Inc. (NASDAQ:TARA)

Bank of America Corp DE boosted its stake in shares of Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) by 53,013.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 194,397 shares of the company's stock after buying an additional 194,031 shares during the period. Bank of America Corp DE owned approximately 0.94% of Protara Therapeutics worth $1,026,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of TARA. Dimensional Fund Advisors LP bought a new stake in shares of Protara Therapeutics during the fourth quarter worth $111,000. BNP Paribas Financial Markets acquired a new stake in shares of Protara Therapeutics in the 4th quarter valued at about $802,000. Geode Capital Management LLC lifted its holdings in shares of Protara Therapeutics by 5.6% in the fourth quarter. Geode Capital Management LLC now owns 179,593 shares of the company's stock valued at $948,000 after purchasing an additional 9,553 shares in the last quarter. Acorn Capital Advisors LLC acquired a new position in shares of Protara Therapeutics during the fourth quarter worth about $6,757,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of Protara Therapeutics during the fourth quarter worth about $11,880,000. Institutional investors own 38.13% of the company's stock.

Insider Transactions at Protara Therapeutics

In related news, insider Jacqueline Zummo sold 21,224 shares of Protara Therapeutics stock in a transaction dated Wednesday, March 26th. The stock was sold at an average price of $4.53, for a total transaction of $96,144.72. Following the completion of the transaction, the insider now owns 98,861 shares in the company, valued at approximately $447,840.33. This trade represents a 17.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 8.40% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

TARA has been the topic of several research reports. Cantor Fitzgerald assumed coverage on Protara Therapeutics in a research note on Friday, March 14th. They issued an "overweight" rating on the stock. Jones Trading upgraded shares of Protara Therapeutics to a "strong-buy" rating and set a $21.00 price objective on the stock in a report on Thursday, May 22nd. Scotiabank assumed coverage on shares of Protara Therapeutics in a research report on Wednesday, April 16th. They issued a "sector outperform" rating and a $12.00 price objective on the stock. Lifesci Capital began coverage on shares of Protara Therapeutics in a research report on Tuesday, March 11th. They issued an "outperform" rating and a $22.00 target price for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $23.00 price target on shares of Protara Therapeutics in a research note on Monday, April 28th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $20.50.

Protara Therapeutics Stock Up 3.1%

Shares of NASDAQ TARA traded up $0.10 during trading hours on Tuesday, hitting $3.37. The company had a trading volume of 317,436 shares, compared to its average volume of 774,178. Protara Therapeutics, Inc. has a 1-year low of $1.60 and a 1-year high of $10.48. The firm's 50 day moving average is $3.53 and its 200-day moving average is $4.22. The stock has a market capitalization of $130.02 million, a P/E ratio of -1.20 and a beta of 1.34.

Protara Therapeutics (NASDAQ:TARA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.18. On average, sell-side analysts predict that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.